Login to Your Account

FDA Panel Votes In Favor Of Nektar's Inhaled Insulin

By Karen Pihl-Carey

Monday, September 12, 2005
An FDA advisory committee recommended approval of Nektar Therapeutics Inc.'s inhaled insulin product, Exubera - offering hope to many Type I and Type II diabetics who, for more than 80 years, had to stick themselves with needles to control their glucose levels. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription